LUNG CANCER

Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations.

Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.

The FDA has lifted the partial clinical hold on the phase 1 YL202-INT-101-01 trial, allowing enrollment to resume in the US for patients with advanced NSCLC harboring EGFR mutations and HR-positive/HER2-negative breast cancer.

In an interview with Targeted Oncology, Aristotelis Tsirigos, PhD, discussed a study evaluating a self-taught artificial intelligence tool that can accurately diagnose cases of adenocarcinoma.

PT217 has received an orphan drug designation from the FDA for the treatment of patients with neuroendocrine carcinoma.

The ON-SITE study has enrolled its first patient to evaluate an AI-based image analysis module for lung cancer.

The FDA-approved regimen is for neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable non–small cell lung cancer.

Following promising data from the phase 1 Deltacel-01 trial, the FDA has given Deltacel plus low-dose radiation therapy a fast track designation in stage IV non–small cell lung cancer.

In the Acclaim-1 and Acclaim-3 trials, prolonged progression-free survival and partial remission were observed with quaratusugene ozeplasmid plus osimertinib and atezolizumab for advanced lung cancer treatment.

The AFFINITY study has finished enrolling participants to evaluate the Aliya pulsed electric field system in patients with stage IV non–small cell lung cancer or lung metastases who are not candidates for surgery.

LP-300, a novel small molecule, shows promise as a potential breakthrough treatment for advanced non–small cell lung cancer in never smokers.

Suresh S. Ramalingam, MD, discussed the practice-changing findings and implications of the phase 3 LAURA study investigating osimertinib for the treatment of patients with EGFR-mutated non–small cell lung cancer.

During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, talked with event participants about adverse events they have observed in their patients after using immune checkpoint inhibitors in the second article of a 2-part series.

While sacituzumab govitecan did not statistically improve overall survival vs docetaxel, there was a numerical improvement observed in patients with non–small cell lung cancer.

Nicolas Girard, MD, PhD, discussed findings from the PALOMA-2 study investigating subcutaneous vs intravenous amivantamab plus lazertinib for previously untreated, EGFR-mutant non–small cell lung cancer.

SenoVax, a novel senolytic immunotherapy for NSCLC, has been submitted as an investigational new drug application to the FDA, initiating a clinical trial to test its efficacy.

The FDA’s Oncologic Drugs Advisory Committee convened to assess the need for rigorous trial designs evaluating perioperative regimens in resectable non–small cell lung cancer.

A phase 2 trial shows that THIO, a new investigational drug, combined with cemiplimab, may be an effective and well-tolerated treatment for patients with advanced non–small cell lung cancer who have exhausted other options.

The first pretreated patient with HER2-altered non–small cell lung cancer was dosed with NVL-330, a novel HER2-selective inhibitor, in the HEROEX-1 trial.

Ajaz M. Khan, MD, MBA, CPE, provides his insights into the novel biomarkers and up-front immunotherapies that are changing the landscape of treatment for patients with lung cancer.

During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, discusses the use of immunotherapy combinations based on patients PD-L1 expression in the first article of a 2-part series.

In an interview, Aakash Desai, MD, MPH, discussed significant lung cancer treatment advancements that were highlighted at ASCO 2024.

Aristotelis Tsirigos, PhD, discusses a self-taught artificial intelligence tool being developed to accurately diagnose cases of adenocarcinoma.

Jessica Paulus, ScD, discussed a study investigating real-world trends in lung cancer staging among community oncology practices.

Salma Jabbour, MD, discusses the implications of a 4-year follow-up of the KEYNOTE-799 study of pembrolizumab and chemoradiotherapy in stage III non–small cell lung cancer.